查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606308

癌症微生物組定序市場：按產品、技術、應用和最終用戶分類 - 2025-2030 年全球預測

Cancer Microbiome Sequencing Market by Product (Kits & Assays, Service, Software), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症微生物組定序市值為17.4億美元，預計到2024年將達到18.4億美元，複合年成長率為5.79%，到2030年將達到25.9億美元。

癌症微生物組定序的範圍包括分析癌症患者體內的微生物群落，以了解它們對癌症發生、進展和治療反應的影響。這個不斷發展的領域至關重要，因為微生物組在調節免疫反應和藥物療效中的作用越來越受到人們的認可，使其成為個人化醫療策略不可或缺的一部分。癌症微生物組定序的應用涵蓋腫瘤學研究、治療開發和診斷平台。它提供了對與不同癌症類型相關的微生物變化的深入了解，並可能產生新的生物標記和治療標靶。最終用途範圍包括學術機構、生物技術公司和醫療保健提供者，希望將微生物組見解轉化為臨床實踐。

主要市場統計
基準年[2023] 17.4億美元
預計年份 [2024] 18.4億美元
預測年份 [2030] 25.9億美元
複合年成長率（%） 5.79%

影響該市場的主要成長要素包括定序技術的進步、癌症研究投資的增加以及對微生物相關健康影響的認知不斷提高。開發以微生物為基礎的療法、伴同性診斷和精準醫學方法的時機已經成熟。公司可以透過與研究機構合作並利用人工智慧來了解複雜的微生物與癌症相互作用而受益。然而，市場面臨全面微生物定序高成本、資料標準化挑戰以及需要強力的法規結構等限制。微生物與癌症相互作用的複雜性和缺乏臨床共識給臨床傳播帶來了重大挑戰。

業務成長的創新領域包括開發非侵入性診斷工具、整合微生物組資料和基因組學以進行全面的癌症分析，以及針對特定癌症相關微生物群的新療法，例如生物製劑。市場的本質是高度動態的，由快速的技術進步和跨學科合作所驅動。公司應專注於針對利基癌症和微生物物種的研究，以及擴充性的、特異性患者的解決方案。為了利用潛在的商機，策略性舉措包括促進與學術界的合作、投資跨學科團隊以及倡導監管透明度。

市場動態：揭示快速發展的癌症微生物組定序市場的關鍵市場洞察

供需的動態交互作用正在改變癌症微生物組定序市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症患者數量增加
    • 政府促進癌症預防、診斷和治療的舉措
    • 研究活動增加，人們對腸道微生物組重要性的認知不斷提高
  • 市場限制因素
    • 使用定序服務成本高且缺乏熟練人員
  • 市場機會
    • 次世代定序儀的進展
    • 利用人工智慧、機器學習和生物資訊學實現癌症檢測
  • 市場挑戰
    • 與資料分析相關的技術限制和困難

波特五力：駕馭癌症微生物定序市場的策略工具

波特的五力框架是了解癌症微生物組定序市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症微生物組定序市場的外部影響

外部宏觀環境因素在塑造癌症微生物組定序市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症微生物組定序市場的競爭格局

對癌症微生物組定序市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症微生物組定序市場供應商的績效評估

FPNV定位矩陣是評估癌症微生物組定序市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了癌症微生物組定序市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，癌症微生物組定序市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症患者數量不斷增加
      • 政府促進癌症預防、診斷和治療的舉措
      • 研究活動增加，人們對腸道微生物組重要性的認知不斷提高
    • 抑制因素
      • 使用定序服務的成本較高，且技術人員短缺。
    • 機會
      • 次世代定序的進展
      • 利用人工智慧、機器學習和生物資訊學實現癌症檢測
    • 任務
      • 與資料分析相關的技術限制和困難
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症微生物組定序市場：依產品

  • 套件和檢測
  • 服務
  • 軟體

第7章癌症微生物組定序市場：依技術分類

  • 次世代定序
  • 聚合酵素鏈鎖反應

第8章癌症微生物組定序市場：依應用分類

  • 診斷
  • 轉化研究

第 9 章癌症微生物組定序市場：依最終用戶分類

  • 學術研究所
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第10章美洲癌症微生物組定序市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症微生物組定序市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症微生物組定序市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Athos Therapeutics Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb
  • CosmosID
  • Creative Biolabs
  • Evelo Biosciences
  • EzBiome
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • Illumina, Inc.
  • LC Sciences
  • Merck KGaA
  • Metagen Therapeutics
  • MV BioTherapeutics SA
  • Norgen Biotek Corp.
  • Novogene Co, Ltd.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Vedanta Biosciences.
  • Viome Life Sciences, Inc.
Product Code: MRR-5C6F41F5AF92

The Cancer Microbiome Sequencing Market was valued at USD 1.74 billion in 2023, expected to reach USD 1.84 billion in 2024, and is projected to grow at a CAGR of 5.79%, to USD 2.59 billion by 2030.

The scope of cancer microbiome sequencing encompasses the analysis of microbial communities within cancer patients to understand their impact on cancer development, progression, and treatment response. This growing field is vital due to the increasing recognition of the microbiome's role in modulating immune responses and drug efficacy, making it an essential component of personalized medicine strategies. The application of cancer microbiome sequencing spans oncology research, therapeutic development, and diagnostic platforms. It offers insights into the microbial alterations associated with different cancer types, potentially leading to novel biomarkers and therapeutic targets. The end-use scope involves academic institutions, biotechnology companies, and healthcare providers looking to integrate microbiome insights into clinical practice.

KEY MARKET STATISTICS
Base Year [2023] USD 1.74 billion
Estimated Year [2024] USD 1.84 billion
Forecast Year [2030] USD 2.59 billion
CAGR (%) 5.79%

Key growth factors influencing this market include advancements in sequencing technologies, rising investments in cancer research, and heightened awareness of microbiome-related health implications. Opportunities are ripe in developing microbial-based therapeutics, companion diagnostics, and precision medicine approaches. Companies can benefit from partnerships with research institutions and leveraging AI to elucidate complex microbiome-cancer interactions. However, the market faces limitations such as high costs of comprehensive microbial sequencing, challenges in data standardization, and the need for robust regulatory frameworks. The complexity of microbiome-cancer interactions and the current lack of clinical consensus pose significant challenges to widespread clinical adoption.

Innovative areas for business growth include the development of non-invasive diagnostic tools, integration of microbiome data with genomics for comprehensive cancer profiling, and novel probiotic formulations targeting specific cancer-related microbiota. The nature of the market is highly dynamic, driven by rapid technological advancements and cross-disciplinary collaborations. Businesses should focus on targeted research in niche cancer types or microbial species, alongside scalable patient-specific solutions. To capitalize on the potential opportunities, fostering collaborations with academia, investing in cross-disciplinary teams, and advocating for increased regulatory clarity are recommended strategic moves.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Microbiome Sequencing Market

The Cancer Microbiome Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of cancer cases across the world
    • Government initiatives to promote cancer prevention, diagnosis, and care
    • Growing number of research activities and increasing awareness about the significance of gut microbiome
  • Market Restraints
    • High cost of availing sequencing services and lack of skilled personnel
  • Market Opportunities
    • Advancements in next-generation sequencing
    • Utilization of AI, ML, and bioinformatics to enable cancer detection
  • Market Challenges
    • Technical limitations and difficulties associated with data analysis

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Microbiome Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Microbiome Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Microbiome Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Microbiome Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Microbiome Sequencing Market

A detailed market share analysis in the Cancer Microbiome Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Microbiome Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Microbiome Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Microbiome Sequencing Market

A strategic analysis of the Cancer Microbiome Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Microbiome Sequencing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Athos Therapeutics Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb, CosmosID, Creative Biolabs, Evelo Biosciences, EzBiome, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, Illumina, Inc., LC Sciences, Merck KGaA, Metagen Therapeutics, MV BioTherapeutics SA, Norgen Biotek Corp., Novogene Co, Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Vedanta Biosciences., and Viome Life Sciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Microbiome Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Kits & Assays, Service, and Software.
  • Based on Technology, market is studied across Next-Generation Sequencing and Polymerase Chain Reaction.
  • Based on Application, market is studied across Diagnostics and Translational Research.
  • Based on End User, market is studied across Academic & Research Institutes, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer cases across the world
      • 5.1.1.2. Government initiatives to promote cancer prevention, diagnosis, and care
      • 5.1.1.3. Growing number of research activities and increasing awareness about the significance of gut microbiome
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of availing sequencing services and lack of skilled personnel
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation sequencing
      • 5.1.3.2. Utilization of AI, ML, and bioinformatics to enable cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations and difficulties associated with data analysis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Microbiome Sequencing Market, by Product

  • 6.1. Introduction
  • 6.2. Kits & Assays
  • 6.3. Service
  • 6.4. Software

7. Cancer Microbiome Sequencing Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing
  • 7.3. Polymerase Chain Reaction

8. Cancer Microbiome Sequencing Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostics
  • 8.3. Translational Research

9. Cancer Microbiome Sequencing Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Hospitals & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Cancer Microbiome Sequencing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Microbiome Sequencing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Microbiome Sequencing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Athos Therapeutics Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Bristol-Myers Squibb
  • 7. CosmosID
  • 8. Creative Biolabs
  • 9. Evelo Biosciences
  • 10. EzBiome
  • 11. F. Hoffmann-La Roche AG
  • 12. Ferring Pharmaceuticals
  • 13. Illumina, Inc.
  • 14. LC Sciences
  • 15. Merck KGaA
  • 16. Metagen Therapeutics
  • 17. MV BioTherapeutics SA
  • 18. Norgen Biotek Corp.
  • 19. Novogene Co, Ltd.
  • 20. Qiagen NV
  • 21. Thermo Fisher Scientific Inc.
  • 22. Vedanta Biosciences.
  • 23. Viome Life Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER MICROBIOME SEQUENCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER MICROBIOME SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER MICROBIOME SEQUENCING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023